GenesisCare and SeeTreat to bring personalised Offline Adaptive Monitoring to more than 40 radiation oncology centres across Australia
Leading Australian cancer care provider, GenesisCare, is pleased to be collaborating with SeeTreat to enable suitable prostate, breast, and head and neck cancer patients access to the latest technology in offline adaptive treatment assessment. SeeTreat’s TGA‑approved ART.1 software will be rolled out through a national pilot at GenesisCare from July 2026 to support automated, adaptive treatment evaluation for eligible patients.
GenesisCare Chief Medical Officer, Dr Marcus Dreosti, explains that “whilst radiation treatment is proven to be a safe and highly effective cancer treatment, unwanted toxicities and side effects can occur due to changes in a patient’s anatomy over the course of treatment. Optimising treatment post commencement, called ‘adaptive radiotherapy’, is labour intensive and complex. We’re excited that through this collaboration with SeeTreat, we now have the opportunity to make adaptive radiotherapy more accessible for patients across our Australian network.”
GenesisCare’s decision to implement the SeeTreat ART.1 tool follows a multidisciplinary study of the software on over 64 head and neck, breast, and prostate cancer patients treated on mixed vendor platforms assessing accuracy, efficiency and patient impact. The study showed significant potential benefits to standardising and scaling adaptive workflows, providing actionable insights to clinicians when they need it.
Radiation Oncologist, Dr Melanie Jackson, shares: “ART.1 is proving to be an easy-to-use tool to help me identify which of my patients would benefit from a new treatment plan and when this is optimal. The efficiency of the software and personalisation of care ensures we match our clinical team’s effort and valuable resource time to achieve the best possible patient outcomes.”
SeeTreat CEO and Founder, Dr Trang Nguyen said “GenesisCare is a truly patient-centric and innovative organisation with passionate doctors and clinical staff constantly striving to deliver the best care possible. Working with the GenesisCare team is a pleasure and we’re proud to be collaborating with the group.”
SeeTreat’s ART.1 software has a UKCA mark, CE mark, Australian TGA approval and is FDA pending.
Media contact information
Contact our media team directly for futher information:
We’re excited that through this collaboration with SeeTreat, we now have the opportunity to make adaptive radiotherapy more accessible for patients across our Australian network.
- Dr Marcus Dreosti, Chief Medical Officer, GenesisCare
